Kaisa Huhtinen
PhD, Adjunct Professor in Cancer Biology
kaisa.huhtinen@utu.fi +358 29 450 2645 +358 50 572 6733 Kiinamyllynkatu 10 Turku Office: D5038 ORCID identifier: https://orcid.org/0000-0001-9685-5246 |
Areas of expertise
Ovarian cancer; personalized medicine; early diagnostics; prediction; prognosis; biomarker; genomics; drug target; interdicipline research;
Ovarian cancer; personalized medicine; early diagnostics; prediction; prognosis; biomarker; genomics; drug target; interdicipline research;
Biography
Research
Publications
- Analysis of single-cell RNA-seq data from ovarian cancer samples before and after chemotherapy links stress-related transcriptional profile with chemotherapy resistance (2020)
- bioRxiv
(Other publication) - A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions (2020)
- Scientific Data
(A1 Refereed original research article in a scientific journal) - Exploratory Analysis of CA125-MGL and –STn Glycoforms in the Differential Diagnostics of Pelvic Masses (2020)
- The Journal of Applied Laboratory Medicine
(A1 Refereed original research article in a scientific journal) - Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 (2020)
- Communications Biology
(A1 Refereed original research article in a scientific journal) - HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma (2020)
- Acta Oncologica
(A1 Refereed original research article in a scientific journal) - RNA-seq analysis of high-grade serous ovarian cancer patients before and after chemotherapy reveals chemoresistance-associated genes and pathways (2020)
- Clinical Cancer Research
(Other publication) - Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer (2020)
- Clinical Cancer Research
(Other publication) - CtDNA profiling to predict prognosis and optimize treatment in high-grade serous ovarian cancer (2019)
- Clinical Cancer Research
(Other publication) - Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources (2019)
- The Journal of Applied Laboratory Medicine
(A1 Refereed original research article in a scientific journal) - Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer (2019)
- JCO Precision Oncology
(A1 Refereed original research article in a scientific journal)



